Skip to content

Dissolving Effects of Cicer Arietinum on Renal and ureteral Stones

Clinical Trial of Dissolving Effects of Cicer Arietinum on Renal and ureteral Stones

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017042433623N1
Enrollment
70
Registered
2017-06-24
Start date
2017-07-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Calculus of kidney and ureter. Calculus of kidney and ureter

Interventions

Intervention 1: Each participant in control group will given 2 placebo capsules two time a day for one month. Intervention 2: Each participant in intervention group will given 2 capsules contain amoun
Treatment - Drugs
Each participant in control group will given 2 placebo capsules two time a day for one month.
Each participant in intervention group will given 2 capsules contain amount 10 gr of prepared Cicer Arietinium extract capsule two time a day for one month.

Sponsors

School of Iranian Traditional Medicine. Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Renal or ureteral stone diagnosis with size between 6 to 10 millimeter by urologist in any composition and using sonography, K.U.B and/or C.T scan(without contrast); Age between 18 to 50 in both genders; Patient should not be affected by any grade of hydronephrosis; Anatomical position of stones in renal pelvis, calyxes, upper-middle-lower portion of ureter; Controllable pain, nausea and vomiting by oral NSAIDS and oral anti emetics; Intending to participation in study, inform consent and signing it's written form before recruiting in the study; Not consumption any chemical or herbal drug at least one month before entering the study; Not consumption the nephrolithogen drugs; Normal range of renal function tests(BUN, Cr); Normal range of liver function tests(SGPT, SGOT, Alk Phos); Absence any symptom and sign of urinary tract infection. Exclusion criteria: Patients with renal or ureteral stone/s less than 5 mm or more than 11 mm in size; Affecting by urinary stone complications(any grade of hydronephrosis and U.T.I); Patients who need to surgery, other procedures or emergency interventions; Uncontrolled pain, nausea and vomiting despite using oral NSAIDS and oral anti emetics; Consumption other types of chemical or herbal drugs except those prescribed in this study; Subjects intending to withdraw at any time during the course of study; Having a history of significant problems(diabetes mellitus, renal dysfunctions, hepatic dysfunctions and peptic ulcer); Pregnancy; Lactating.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Change in size of stone/s. Timepoint: before intervention and just after termination of intervention. Method of measurement: in millimeter by using ruler (visual).

Secondary

MeasureTime frame
Change in plasma concentration of BUN ? Creatinine ? ALT? AST. Timepoint: before intervention and just after termination of intervention. Method of measurement: mg/dl for BUN and Creatinine , u/lit for AST and ALT.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBiglarkhani Mahdi

Iran University of Medical Sciences, School of Iranian Traditional Medicine

mahdibiglarkhani@gmail.com+98 81 3837 2242

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026